Development and Validation of RP-HPLC method for simultaneous Estimation of Metformin HCl and Gliclazide
Abstract
A new, simple and validated RP-HPLC method was developed for simultaneous estimation of Metformin HCl (MET) and Gliclazide (GLZ). The separation was achieved by using mobile phase Methanol: 10 mM Phosphate buffer (pH 3) 70: 30% v/v on Kinetics C18 column (250 × 4.6 mm, 5μ). The flow rate was 1 ml/min. The detection was carried out at wavelength 230 nm. The retention time of MET and GLZ was found to be 2.20 min and 4.67 min, respectively. Calibration curves for MET and GLZ were found to be linear in the range of 10–60 μg/ml and 2–12 μg/ml, respectively. The proposed method was validated as per ICH guideline Q2 (R1). The validation parameters studied were linearity, accuracy, precision, specificity and robustness. All validation parameters were found within the acceptable range.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.